Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $260

Benzinga · 2d ago
Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $250 to $260.